Anika Therapeutics (ANIK) Asset Writedowns and Impairment (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Asset Writedowns and Impairment data on file, last reported at $111000.0 in Q1 2026.

• Asset Writedowns and Impairment for Q1 2026 came in at $111000.0, down 86.66% year-over-year; the trailing twelve-month figure through Mar 2026 was -$721000.0 (up 96.61% YoY), and the FY2024 annual result was $195000.0, down 94.16% from the prior year.
• Asset Writedowns and Impairment advanced to $111000.0 in Q1 2026 per ANIK's latest filing, from -$5.0 million in the prior quarter.
• Over five years, Asset Writedowns and Impairment peaked at $3.1 million in Q3 2024 and troughed at -$25.9 million in Q4 2024.
• A 5-year average of -$1.0 million and a median of $207500.0 in 2022 frame the typical range for Asset Writedowns and Impairment.
• On a YoY basis, Asset Writedowns and Impairment climbed as much as 1922.55% in 2024 and fell as far as 966.23% in 2024.
• A 5-year view of Asset Writedowns and Impairment shows it stood at -$448000.0 in 2022, then soared by 766.96% to $3.0 million in 2023, then tumbled by 966.23% to -$25.9 million in 2024, then soared by 80.8% to -$5.0 million in 2025, then surged by 102.23% to $111000.0 in 2026.
• Business Quant data shows ANIK's Asset Writedowns and Impairment at $111000.0 in Q1 2026, -$5.0 million in Q4 2025, and $1.1 million in Q3 2025.